Predictors of Hyperkalemia Risk after Hypertension Control with Aldosterone Blockade according to the Presence or Absence of Chronic Kidney Disease

Conclusion: Spironolactone was well tolerated by selected CKD patients. The risk of serious hyperkalemia or a significant reduction of eGFR appears to be low. Strict monitoring over the first month of treatment followed by standard surveillance for angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers is suggested.Nephron Clin Pract 2014;128:381-386
Source: Nephron Clinical Practice - Category: Urology & Nephrology Source Type: research